BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 26936765)

  • 1. Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy.
    Piras A; Collin L; Grüninger F; Graff C; Rönnbäck A
    Acta Neuropathol Commun; 2016 Mar; 4():22. PubMed ID: 26936765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decrease of neuronal FKBP4/FKBP52 modulates perinuclear lysosomal positioning and MAPT/Tau behavior during MAPT/Tau-induced proteotoxic stress.
    Chambraud B; Daguinot C; Guillemeau K; Genet M; Dounane O; Meduri G; Poüs C; Baulieu EE; Giustiniani J
    Autophagy; 2021 Nov; 17(11):3491-3510. PubMed ID: 33459145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
    Ferrer I; Blanco R; Carmona M; Puig B
    J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Blanco R; Carmona M; Ribera R; Goutan E; Puig B; Rey MJ; Cardozo A; Viñals F; Ribalta T
    Brain Pathol; 2001 Apr; 11(2):144-58. PubMed ID: 11303790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease.
    Ando K; Tomimura K; Sazdovitch V; Suain V; Yilmaz Z; Authelet M; Ndjim M; Vergara C; Belkouch M; Potier MC; Duyckaerts C; Brion JP
    Neurobiol Dis; 2016 Oct; 94():32-43. PubMed ID: 27260836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of the astrocytic tau pathology to synapse loss in progressive supranuclear palsy and corticobasal degeneration.
    Briel N; Pratsch K; Roeber S; Arzberger T; Herms J
    Brain Pathol; 2021 Jul; 31(4):e12914. PubMed ID: 33089580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration.
    Gentry EG; Henderson BW; Arrant AE; Gearing M; Feng Y; Riddle NC; Herskowitz JH
    J Neurosci; 2016 Jan; 36(4):1316-23. PubMed ID: 26818518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-repeat tauopathy sharing pathological and biochemical features of corticobasal degeneration and progressive supranuclear palsy.
    Katsuse O; Iseki E; Arai T; Akiyama H; Togo T; Uchikado H; Kato M; de Silva R; Lees A; Kosaka K
    Acta Neuropathol; 2003 Sep; 106(3):251-60. PubMed ID: 12802605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
    Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
    J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration.
    Yoshida M
    Neuropathology; 2014 Dec; 34(6):555-70. PubMed ID: 25124031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid.
    Boman A; Svensson S; Boxer A; Rojas JC; Seeley WW; Karydas A; Miller B; Kågedal K; Svenningsson P
    J Parkinsons Dis; 2016 Apr; 6(2):307-15. PubMed ID: 27061067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype.
    Koga S; Kouri N; Walton RL; Ebbert MTW; Josephs KA; Litvan I; Graff-Radford N; Ahlskog JE; Uitti RJ; van Gerpen JA; Boeve BF; Parks A; Ross OA; Dickson DW
    Acta Neuropathol; 2018 Sep; 136(3):389-404. PubMed ID: 29926172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strain-specific clearance of seed-dependent tau aggregation by lithium-induced autophagy.
    Uddin MN; Elahi M; Shimonaka S; Kakuta S; Ishiguro K; Motoi Y; Hattori N
    Biochem Biophys Res Commun; 2021 Mar; 543():65-71. PubMed ID: 33517128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies.
    Pires G; McElligott S; Drusinsky S; Halliday G; Potier MC; Wisniewski T; Drummond E
    Acta Neuropathol Commun; 2019 Dec; 7(1):195. PubMed ID: 31796108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unexpected abundance of pathological tau in progressive supranuclear palsy white matter.
    Zhukareva V; Joyce S; Schuck T; Van Deerlin V; Hurtig H; Albin R; Gilman S; Chin S; Miller B; Trojanowski JQ; Lee VM
    Ann Neurol; 2006 Sep; 60(3):335-45. PubMed ID: 16823854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive Supranuclear Palsy and Corticobasal Degeneration.
    Coughlin DG; Dickson DW; Josephs KA; Litvan I
    Adv Exp Med Biol; 2021; 1281():151-176. PubMed ID: 33433875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy brains.
    Malarte ML; Gillberg PG; Kumar A; Bogdanovic N; Lemoine L; Nordberg A
    Mol Psychiatry; 2023 Mar; 28(3):1272-1283. PubMed ID: 36447011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4.
    Tsuboi Y; Wszolek ZK; Graff-Radford NR; Cookson N; Dickson DW
    Neuropathol Appl Neurobiol; 2003 Oct; 29(5):503-10. PubMed ID: 14507342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant Neuronal Tau Deposition and FKBP52 Decrease Is an Early Feature of Different Human and Experimental Tauopathies.
    Meduri G; Guillemeau K; Daguinot C; Dounane O; Genet M; Ferrara L; Chambraud B; Baulieu EE; Giustiniani J
    J Alzheimers Dis; 2023; 94(1):313-331. PubMed ID: 37248902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.